Biochemical Discovery Intern
- Employer
- Mammoth Biosciences
- Location
- Brisbane, CA
- Start date
- Dec 7, 2021
View more
- Discipline
- Science/R&D, Biology, Cell Biology, Chemistry, Laboratory
- Required Education
- Associate Degree
- Position Type
- Full time
- Hotbed
- Biotech Bay
Job Details
KEY RESPONSIBILITIES
- Work directly with Scientists and Research Associates to biochemically characterize novel Cas proteins in terms of thermostability, target sensitivity, and other traits of interest
- Assist in routine lab operations (reagent preparation, etc.)
- Document work and be able to communicate findings and reasoning with other team members
- The intern will specifically investigate the relationship between crispr RNA (crRNA) characteristics and protein function and activity
- The intern will learn/use basic wet lab techniques such as: PCR, plate based assays, bacterial culturing, cloning/transforming, and others as needed
REQUIRED QUALIFICATIONS
- Pursuing degree in molecular and cellular biology, biochemistry, or related field
- Laboratory experience in biology or biochemistry through courses or undergraduate research
PREFERRED QUALIFICATIONS
- 1 year of academic part-time research or 1 Summer of previous lab internship experience
- Curiosity and eagerness to learn about biological concepts and work in industry
As CRISPR-Cas is a new and rapidly developing technology, no specific experience with CRISPR is required -- only a desire to learn! :)
Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC, along with leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.
TEAM
Our small-size proteins, such as Cas14 and CasPhi, are poised to transform disease treatment enabling novel editing approaches and delivery options that are difficult to achieve or not even possible with previously described CRISPR-Cas systems. Our teams are responsible for discovering and engineering novel CRISPR systems, establishing CRISPR-based diagnostics, and translating our unique CRISPR technology into therapeutic treatments with the ultimate goal of cures for indications with high medical need.
It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.
Company
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
- Website
- http://www.mammoth.bio/
- Phone
- (650) 294-8583
- Location
-
South San Francisco
CA
94080
United States
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert